The PARADIGM-HF trial showed that Sacubitril/Valsartan (LCZ696), with the combination of neprilysin inhibitor and angiotensin II receptor blocker (ARB) could reduce both heart failure (HF) hospitalization and cardiovascular mortality by 20% in comparison with Enalapril [1]. The gene discussed is MME; the disease is hydrops fetalis.